# EDGAR Filing Document

**Accession Number:** 0001070494
**File Stem:** 0001193125-26-265809
**Filing Date:** 2026-6
**Character Count:** 17861
**Document Hash:** d79be759401ea2935ffc720d8a6f7024
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-265809.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001193125-26-265809

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260610

**DATE AS OF CHANGE**: 20260610

**EFFECTIVENESS DATE**: 20260610

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACADIA PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001070494
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061376651
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296668
- **FILM NUMBER:** 261079658

**BUSINESS ADDRESS:**
- **STREET 1:** 12830 EL CAMINO REAL
- **STREET 2:** SUITE 400
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 858-558-2871

**MAIL ADDRESS:**
- **STREET 1:** 12830 EL CAMINO REAL
- **STREET 2:** SUITE 400
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**As filed with the Securities and Exchange Commission on June 10, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## ACADIA PHARMACEUTICALS INC.
**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **06-1376651** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**12830 El Camino Real, Suite 400** 

**San Diego, CA 92130** 

**(Address of Principal Executive Offices, Including Zip Code)** 

**Acadia Pharmaceuticals Inc.** 

**2024 Equity Incentive Plan, as amended** 

**(Full title of the plan)** 

**Jennifer J. Rhodes** 

**Executive Vice President, Chief Legal Officer & Secretary** 

**Acadia Pharmaceuticals Inc.** 

**12830 El Camino Real, Suite 400** 

**San Diego, CA 92130** 

**(Name and Address of Agent for Service)** 

**(858) 558-2871** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Carlos Ramirez, Esq.** 

**Cooley LLP** 

**10265 Science Center Drive** 

**San Diego, CA 92121-1117** 

**(858) 550-6000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E** 

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Acadia Pharmaceuticals Inc. (the "Registrant") with the Securities and Exchange Commission (the "SEC") for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective. The Registrant previously registered its shares of common stock, par value $0.0001 per share, for issuance under the Registrant's 2024 Equity Incentive Plan, as amended, under the Registrant's Registration Statement on Form S-8 filed with the SEC on [May 29, 2024](http://www.sec.gov/Archives/edgar/data/1070494/000119312524149130/d840673ds8.htm) (File No. 333-279784) (the "Prior Registration Statement"). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statement.

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q, filed August 6, 2015).](http://www.sec.gov/Archives/edgar/data/1070494/000119312515281018/d937801dex31.htm) |
| 4.2 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K, filed February 25, 2021).](http://www.sec.gov/Archives/edgar/data/1070494/000156459021008372/acad-ex32_633.htm) |
| 4.3 | [Amended and Restated Bylaws, effective on and after April 15, 2025 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed April 16, 2025).](http://www.sec.gov/Archives/edgar/data/1070494/000119312525082809/d905282dex31.htm) |
| 4.4 | [Form of common stock certificate of the Registrant (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-52492, filed December 21, 2000).](http://www.sec.gov/Archives/edgar/data/1070494/000091205700054458/a2033472zex-4_1.txt) |
| 5.1\* | [Opinion of Cooley LLP.](d149581dex51.htm) |
| 23.1\* | [Consent of Independent Registered Public Accounting Firm.](d149581dex231.htm) |
| 23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](d149581dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page).](#sig) |
| 99.1 | [Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed May 29, 2026).](http://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/d140910dex101.htm) |
| 99.2 | [Forms of Standard Stock Option Grant Notice and Stock Option Agreement under the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.2 to Registration Statement No. 333-279784).](http://www.sec.gov/Archives/edgar/data/1070494/000119312524149130/d840673dex992.htm) |
| 99.3 | [Forms of Standard Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to Registration Statement No. 333-279784).](http://www.sec.gov/Archives/edgar/data/1070494/000119312524149130/d840673dex993.htm) |
| 99.4 | [Forms of Director Stock Option Grant Notice and Stock Option Agreement under the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to Registration Statement No. 333-279784).](http://www.sec.gov/Archives/edgar/data/1070494/000119312524149130/d840673dex994.htm) |
| 99.5 | [Forms of Director Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.5 to Registration Statement No. 333-279784).](http://www.sec.gov/Archives/edgar/data/1070494/000119312524149130/d840673dex995.htm) |
| 99.6 | [Forms of Standard Performance Stock Unit Grant Notice and Performance Stock Unit Agreement under the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q, filed August 7, 2025).](http://www.sec.gov/Archives/edgar/data/1070494/000095017025104295/acad-ex10_5.htm) |
| 107\* | [Filing Fee Table.](d149581dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on June 10, 2026.

---

| | |
|:---|:---|
| **ACADIA PHARMACEUTICALS INC.** | **ACADIA PHARMACEUTICALS INC.** |
| By: | /s/ Catherine Owen Adams |
|  | Catherine Owen Adams |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Catherine Owen Adams and Jennifer J. Rhodes, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Catherine Owen Adams<br> Catherine Owen Adams | Chief Executive Officer and Director<br> *(Principal Executive Officer)* | June 10, 2026 |
| /s/ Mark C. Schneyer<br> Mark C. Schneyer | Executive Vice President and Chief Financial Officer<br> *(Principal Financial Officer)* | June 10, 2026 |
| /s/ James K. Kihara<br> James K. Kihara | Senior Vice President, Finance<br> *(Principal Accounting Officer)* | June 10, 2026 |
| /s/ Stephen R. Biggar<br> Stephen R. Biggar | Chairman of the Board | June 10, 2026 |
| /s/ Julian C. Baker<br> Julian C. Baker | Director | June 10, 2026 |
| /s/ Laura A. Brege<br> Laura A. Brege | Director | June 10, 2026 |
| /s/ James M. Daly<br> James M. Daly | Director | June 10, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Elizabeth A. Garofalo<br> Elizabeth A. Garofalo | Director | June 10, 2026 |
| /s/ Edmund P. Harrigan<br> Edmund P. Harrigan | Director | June 10, 2026 |
| /s/ Adora Ndu<br> Adora Ndu | Director | June 10, 2026 |
| /s/ Jonathan M. Poole<br> Jonathan M. Poole | Director | June 10, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g149581g0605235025680.jpg)

Carlos Ramirez

T: +1 858 550 6157

cramirez@cooley.com

June 10, 2026

Acadia Pharmaceuticals Inc.

12830 El Camino Real, Suite 400

San Diego, CA 92130

Ladies and Gentlemen:

We have acted as counsel to Acadia Pharmaceuticals Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***"), covering the offering of up to 5,209,670 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share, issuable pursuant to the Company's 2024 Equity Incentive Plan (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectus, (b) the Plan, (c) the Company's certificate of incorporation and bylaws, each as currently in effect, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and the related prospectus, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

10265 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM

------

![LOGO](g149581g0605235025680.jpg)

Acadia Pharmaceuticals Inc.

June 10, 2026

Page Two

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Cooley LLP | Cooley LLP |
| By: | /s/ Carlos Ramirez |
|  | Carlos Ramirez |

---

10265 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan, as amended, of our reports dated February 25, 2026, with respect to the consolidated financial statements and schedule of Acadia Pharmaceuticals Inc. and the effectiveness of internal control over financial reporting of Acadia Pharmaceuticals Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

June 10, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**ACADIA PHARMACEUTICALS INC**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan, as amended | Other | 5209670 | $21.67 | $112893548.90 | 0.0001381 | $15590.60 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $112893548.90  |  | $15590.60  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $15590.60  |

---

 **Offering Note** <br>

<sup>1</sup> The amount being registered represents additional shares of common stock of Acadia Pharmaceuticals Inc. (the "Registrant") available for issuance under the Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan, as amended (the "2024 Plan"), which amount consists of 4,975,000 new shares plus up to 234,670 shares that were available for future grants under the Acadia Pharmaceuticals Inc. 2024 Inducement Plan but that are now reserved for future grants under the 2024 Plan pursuant to the approval of the Registrant's stockholders at the Registrant's annual meeting of stockholders held on May 29, 2026). Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2024 Plan as a result of any stock split, stock dividend, recapitalization or other similar transaction. The proposed maximum offering price per unit and maximum aggregate offering price are estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and (h) under the Securities Act and based upon the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Global Select Market on June 4, 2026, which date is within five business days prior to the filing of this Registration Statement.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---